MAP2K7 and cancer: In addition to MET TKIs, other targeted therapies including inhibitors targeting downstream signaling hub proteins such as MEK, ERK, AKT, and PI3K have also emerged in preclinical investigations and translational studies relating to MET-aberrant cancers (Hu et al., 2025; Qin et al., 2023; Turke et al., 2012).